My NCBI | Sign In
RSS Settings
  • Search: chronic myelogenous leukemia AND genetics AND review[pt]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 878

    1.

    NCCN task force report: molecular markers in leukemias and lymphomas.

    Radich JP, Zelenetz AD, Chan WC, Croce CM, Czuczman MS, Erba HP, Horning SJ, Houldsworth J, Smith BD, Snyder DS, Sundar HM, Wetzler M, Winter JN.

    J Natl Compr Canc Netw. 2009 Jul;7 Suppl 4:S1-34, quiz S35-6. Review.PMID: 19635230 [PubMed - indexed for MEDLINE]Related articles

    2.

    Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.

    Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ.

    FEBS J. 2009 Nov;276(21):6050-62. Epub 2009 Sep 29. Review.PMID: 19788418 [PubMed - indexed for MEDLINE]Related articles

    3.

    [Chronic myeloid leukemia in the 21st century: biology and treatment]

    Chávez-González MA, Ayala-Sánchez M, Mayani H.

    Rev Invest Clin. 2009 May-Jun;61(3):221-32. Review. Spanish. PMID: 19736811 [PubMed - indexed for MEDLINE]Related articles

    4.

    The impact of gene profiling in chronic myeloid leukaemia.

    Yong AS, Melo JV.

    Best Pract Res Clin Haematol. 2009 Jun;22(2):181-90. Review.PMID: 19698927 [PubMed - indexed for MEDLINE]Related articles

    5.

    How I monitor residual disease in chronic myeloid leukemia.

    Radich JP.

    Blood. 2009 Oct 15;114(16):3376-81. Epub 2009 Aug 6. Review.PMID: 19661271 [PubMed - indexed for MEDLINE]Related articles

    6.

    Imatinib and beyond--exploring the full potential of targeted therapy for CML.

    Quintás-Cardama A, Kantarjian H, Cortes J.

    Nat Rev Clin Oncol. 2009 Sep;6(9):535-43. Epub 2009 Aug 4. Review.PMID: 19652654 [PubMed - indexed for MEDLINE]Related articles

    7.

    Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.

    Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, Pellicano F, Perrotti D, Skoda R, Vannucchi AM.

    Leukemia. 2009 Oct;23(10):1708-15. Epub 2009 Jul 30. Review.PMID: 19641523 [PubMed - indexed for MEDLINE]Related articles

    8.

    Chronic myelogenous leukemia, BCR-ABL1+.

    Vardiman JW.

    Am J Clin Pathol. 2009 Aug;132(2):250-60. Review.PMID: 19605820 [PubMed - indexed for MEDLINE]Related articles

    9.

    Molecular diagnosis of myeloproliferative neoplasms.

    Patnaik MM, Tefferi A.

    Expert Rev Mol Diagn. 2009 Jul;9(5):481-92. Review.PMID: 19580432 [PubMed - indexed for MEDLINE]Related articles

    10.

    Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.

    Keller G, Brassat U, Braig M, Heim D, Wege H, Brümmendorf TH.

    Hematol Oncol. 2009 Sep;27(3):123-9. Review.PMID: 19569255 [PubMed - indexed for MEDLINE]Related articles

    11.

    Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.

    Foroni L, Gerrard G, Nna E, Khorashad JS, Stevens D, Swale B, Milojkovic D, Reid A, Goldman J, Marin D.

    Am J Hematol. 2009 Aug;84(8):517-22. Review.PMID: 19544476 [PubMed - indexed for MEDLINE]Related articles

    12.

    Response dynamics in chronic-phase chronic myeloid leukemia.

    Mauro MJ.

    Clin Lymphoma Myeloma. 2009 Jun;9(3):217-22. Review.PMID: 19525190 [PubMed - indexed for MEDLINE]Related articles

    13.

    Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

    Breccia M, Alimena G.

    Curr Drug Targets. 2009 Jun;10(6):530-6. Review.PMID: 19519355 [PubMed - indexed for MEDLINE]Related articles

    14.

    Kinase drug discovery approaches in chronic myeloproliferative disorders.

    Kumar C, Purandare AV, Lee FY, Lorenzi MV.

    Oncogene. 2009 Jun 18;28(24):2305-13. Epub 2009 May 4. Review.PMID: 19421140 [PubMed - indexed for MEDLINE]Related articles

    15.

    Advances in understanding and management of myeloproliferative neoplasms.

    Vannucchi AM, Guglielmelli P, Tefferi A.

    CA Cancer J Clin. 2009 May-Jun;59(3):171-91. Epub 2009 Apr 15. Review.PMID: 19369682 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

    Quintás-Cardama A, Kantarjian HM, Cortes JE.

    Cancer Control. 2009 Apr;16(2):122-31. Review.PMID: 19337198 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

    Mauro MJ.

    Cancer Control. 2009 Apr;16(2):108-21. Review.PMID: 19337197 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

    Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J, Albitar M.

    Acta Haematol. 2009;121(1):27-31. Epub 2009 Mar 31. Review. No abstract available. PMID: 19332983 [PubMed - indexed for MEDLINE]Related articles

    19.

    t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis.

    Tan J, Cang S, Seiter K, Primanneni S, Ahmed N, Mathews T, Liu D.

    Cancer Invest. 2009 Aug;27(7):718-22. Review.PMID: 19308813 [PubMed - indexed for MEDLINE]Related articles

    20.

    Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem.

    Breccia M, Alimena G.

    Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):21-8. Review.PMID: 19275574 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    20 free full-text articles in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity